Security Snapshot

CITIUS ONCOLOGY, INC. - Common Stock (CTOR) Institutional Ownership

CUSIP: 17331Y109

13F Institutional Holders and Ownership History from Q3 2024 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

19

Shares (Excl. Options)

14,145,277

Price

$0.65

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-102,361
Value change
-$65,363
Number of holders
19
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
93,629,159
SEC-reported price per share
$0.54
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • CTOR - CITIUS ONCOLOGY, INC. - Common Stock is tracked under CUSIP 17331Y109.
  • 19 institutions reported positions in Q2 2026.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 13 to 19 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $8,828,728 to $9,195,137.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 19 institutions filings for Q2 2026.

Open SEC evidence

Security key

17331Y109

Latest holder period

Q2 2026

13F holders

19

13D/G owners

2

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
2
Security
CTOR
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Citius Pharmaceuticals, Inc. 71% -8.8% $59,444,654 66,049,615 0% Citius Pharmaceuticals, Inc. 15 May 2026
ARMISTICE CAPITAL, LLC 10% 0% $6,547,487 +$37,545 9,353,553 +0.58% Armistice Capital, LLC 30 Jun 2026

As of 30 Jun 2026, 19 institutional investors reported holding 14,145,277 shares of CITIUS ONCOLOGY, INC. - Common Stock (CTOR). This represents 15% of the company’s total 93,629,159 outstanding shares.

13F concentration

Top 20 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
15%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ARMISTICE CAPITAL, LLC 9.3% 8,705,589 -5.3% 0.16% $5,659,503
BANK OF AMERICA CORP /DE/ 4.1% 3,835,160 0% 0% $2,492,854
VANGUARD CAPITAL MANAGEMENT LLC 0.58% 546,325 +2.2% 0% $355,111
UBS Group AG 0.36% 334,619 +808% 0% $217,502
GEODE CAPITAL MANAGEMENT, LLC 0.26% 245,407 -7.3% 0% $159,538
VANGUARD FIDUCIARY TRUST CO 0.13% 121,910 0% 0% $79,242
IFP Advisors, Inc 0.11% 107,424 0% 0% $69,836
CITADEL ADVISORS LLC 0.1% 90,586 0% $58,890
NORTHERN TRUST CORP 0.05% 45,746 0% 0% $29,739
STATE STREET CORP 0.05% 42,900 0% 0% $27,889
Virtu Financial LLC 0.02% 21,877 0% $14,000
XTX Topco Ltd 0.02% 20,638 0% $13,417
Tower Research Capital LLC (TRC) 0.01% 13,816 0% $8,982
Arkadios Wealth Advisors 0.01% 11,666 0% 0% $7,584
OSAIC HOLDINGS, INC. 0% 1,000 -90% 0% $650
WELLS FARGO & COMPANY/MN 0% 500 0% $325
BARCLAYS PLC 0% 90 0% $59
MORGAN STANLEY 0% 23 0% $15
Caitong International Asset Management Co., Ltd 0% 1 0% 0% $1
BlackRock, Inc. 0% 0 -100% $0

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
8
Latest
Q2 2026
Rows shown
1-8 of 8
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 14,145,277 $9,195,137 -$65,363 $0.65 19
2026 Q1 14,247,638 $8,828,728 +$4,455,955 $0.62 13
2025 Q4 6,861,177 $6,861,177 -$1,583,956 $1.00 17
2025 Q3 8,357,159 $16,966,429 +$16,255,712 $2.03 16
2025 Q2 227,492 $989,589 +$573,842 $4.35 7
2025 Q1 105,008 $97,657 -$115,519 $0.93 6
2024 Q4 200,884 $230,191 +$180,602 $1.15 11
2024 Q3 41,238 $57,016 +$57,016 $1.39 7
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .